Epcoritamab Plus Rituximab and Lenalidomide Hits Both Primary End Points in R/R Follicular Lymphoma

Blood Cells | Image credit: © Bipul Kumar - stock.adobe.com The combination of epcoritamab-bysp (Epkinly), rituximab (Rituxan), and lenalidomide (Revlimid) demonstrated significant improvements in overall response rate (ORR) and progression-free surv... [545 chars]